




Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARGS


Last Trade:	0.43
Trade Time:	12:34 PM ET May 23, 2017
Change:	-0.01  (-1.124%)
Day Range	0.42 - 0.45
52-Week Range	0.31 - 9.22
Volume	102,177

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 10, 2017

[Argos Provides Update on its ADAPT Trial Following Meeting with FDA](#)

Apr 18, 2017

[Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial](#)

Feb 22, 2017

[Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review](#)

Feb 13, 2017

[Argos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium](#)

Feb 6, 2017

[Argos Therapeutics to Participate in BIO CEO and Investor Conference](#)

Financials [\[View all \]](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Apr 29, 2016

[Proxy Statement \(DEF 14A\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)

Nov 14, 2016

[Quarterly Report \(10-Q\)](#)

Aug 15, 2016

[Quarterly Report \(10-Q\)](#)